Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites Life Science
China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) Life Science
Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity Life Science
Pharnext Announces PXT3003 was Granted Priority Review by the China Food and Drug Administration Life Science
Johnson & Johnson Innovation Announces Launch of Shanghai Lung Cancer Innovation QuickFire Challenge Life Science
Life Science & Technology Weekly 147 – Shanghai Kinetic Acquires US Device Maker Elliquence for $77 Million Life Science, Technology